Skip to content

Comparison of Oliceridine and Sufentanil for Pain Relief and Postoperative Recovery in Patients Undergoing Laparoscopic Cholecystectomy

Analgesic Efficacy of Oliceridine and Quality of Postoperative Recovery in Patients Undergoing Laparoscopic Cholecystectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600130241
Enrollment
Unknown
Registered
2026-08-17
Start date
2026-08-18
Completion date
Unknown
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign gallbladder diseases requiring elective laparoscopic cholecystectomy, including cholelithiasis and gallbladder polyps

Interventions

Sponsors

Sir Run Run Hospital, Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, with a body mass index (BMI) > 18 kg/m^2 and < 28 kg/m^2; 2. American Society of Anesthesiologists (ASA) physical status I-III and scheduled for elective laparoscopic cholecystectomy under general anesthesia at Sir Run Run Hospital, Nanjing Medical University; 3. Either sex; 4. Requiring overnight hospitalization after surgery; 5. Voluntarily participating in the study and providing written informed consent.

Exclusion criteria

Exclusion criteria: 1.Severe respiratory, cardiovascular, renal, or hepatic dysfunction diagnosed before surgery. 2.A history of stroke within the previous 6 months or other diagnosed central nervous system diseases. 3.A history of schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or other psychiatric disorders. 4.A history of alcohol abuse or psychoactive substance dependence. 5.Unable to communicate adequately because of severe visual, hearing, or language impairment. 6.A history of allergy to opioids or contraindications to sufentanil, such as a history of severe respiratory depression or muscle rigidity. 7.Pre-existing cognitive impairment before surgery. 8.Participation in another drug clinical trial within 1 month before the scheduled surgery.

Design outcomes

Primary

MeasureTime frame
Right diaphragmatic excursion after extubation;

Secondary

MeasureTime frame
Time to extubation;Resting visual analogue scale (VAS) pain score;Arterial partial pressure of carbon dioxide (PaCO2);Postoperative nausea and vomiting (PONV);Peripheral oxygen saturation (SpO2);Arterial blood pH;Perioperative adverse events;Postoperative rescue analgesia;Heart rate (HR)?Mean arterial pressure (MAP);

Countries

China

Contacts

Public ContactXiaoyu Liu

Sir Run Run Hospital, Nanjing Medical University

xiaoyu_42c@126.com+86 25 87115655

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026